152 related articles for article (PubMed ID: 38817970)
21. Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.
Schepens B; Ibañez LI; De Baets S; Hultberg A; Bogaert P; De Bleser P; Vervalle F; Verrips T; Melero J; Vandevelde W; Vanlandschoot P; Saelens X
J Infect Dis; 2011 Dec; 204(11):1692-701. PubMed ID: 21998474
[TBL] [Abstract][Full Text] [Related]
22. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
23. Protective antigenic sites identified in respiratory syncytial virus fusion protein reveals importance of p27 domain.
Lee J; Lee Y; Klenow L; Coyle EM; Tang J; Ravichandran S; Golding H; Khurana S
EMBO Mol Med; 2022 Jan; 14(1):e13847. PubMed ID: 34750984
[TBL] [Abstract][Full Text] [Related]
24. Recombinant Sendai viruses expressing fusion proteins with two furin cleavage sites mimic the syncytial and receptor-independent infection properties of respiratory syncytial virus.
Rawling J; Cano O; Garcin D; Kolakofsky D; Melero JA
J Virol; 2011 Mar; 85(6):2771-80. PubMed ID: 21228237
[TBL] [Abstract][Full Text] [Related]
25. Drug Resistance Assessment Following Administration of Respiratory Syncytial Virus (RSV) Fusion Inhibitor Presatovir to Participants Experimentally Infected With RSV.
Stray K; Perron M; Porter DP; Anderson F; Lewis SA; Perry J; Miller M; Cihlar T; DeVincenzo J; Chien JW; Jordan R
J Infect Dis; 2020 Oct; 222(9):1468-1477. PubMed ID: 31971597
[TBL] [Abstract][Full Text] [Related]
26. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
27. Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
Blockus S; Sake SM; Wetzke M; Grethe C; Graalmann T; Pils M; Le Goffic R; Galloux M; Prochnow H; Rox K; Hüttel S; Rupcic Z; Wiegmann B; Dijkman R; Rameix-Welti MA; Eléouët JF; Duprex WP; Thiel V; Hansen G; Brönstrup M; Haid S; Pietschmann T
Antiviral Res; 2020 May; 177():104774. PubMed ID: 32197980
[TBL] [Abstract][Full Text] [Related]
28. Non-glycosylated G protein with CpG ODN provides robust protection against respiratory syncytial virus without inducing eosinophilia.
Kawahara E; Shibata T; Hirai T; Yoshioka Y
Front Immunol; 2023; 14():1282016. PubMed ID: 38169867
[TBL] [Abstract][Full Text] [Related]
29. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.
Lee S; Quan FS; Kwon Y; Sakamoto K; Kang SM; Compans RW; Moore ML
Antiviral Res; 2014 Nov; 111():129-35. PubMed ID: 25239522
[TBL] [Abstract][Full Text] [Related]
30. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
Huang K; Incognito L; Cheng X; Ulbrandt ND; Wu H
J Virol; 2010 Aug; 84(16):8132-40. PubMed ID: 20519399
[TBL] [Abstract][Full Text] [Related]
31. The antiviral efficacies of small-molecule inhibitors against respiratory syncytial virus based on the F protein.
Dai P; Ruan P; Mao Y; Tang Z; Bajinka O; Wu G; Tan Y
J Antimicrob Chemother; 2022 Dec; 78(1):169-179. PubMed ID: 36322459
[TBL] [Abstract][Full Text] [Related]
32. Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.
Brakel KA; Binjawadagi B; French-Kim K; Watts M; Harder O; Ma Y; Li J; Niewiesk S
Vaccine; 2021 Nov; 39(47):6817-6828. PubMed ID: 34702618
[TBL] [Abstract][Full Text] [Related]
33. Antiviral effect of emodin from Rheum palmatum against coxsakievirus B5 and human respiratory syncytial virus in vitro.
Liu Z; Ma N; Zhong Y; Yang ZQ
J Huazhong Univ Sci Technolog Med Sci; 2015 Dec; 35(6):916-922. PubMed ID: 26670446
[TBL] [Abstract][Full Text] [Related]
34. Respiratory syncytial virus entry mechanism in host cells: A general overview.
Cadena-Cruz C; Villarreal Camacho JL; De Ávila-Arias M; Hurtado-Gomez L; Rodriguez A; San-Juan-Vergara H
Mol Microbiol; 2023 Sep; 120(3):341-350. PubMed ID: 37537859
[TBL] [Abstract][Full Text] [Related]
35. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
McGinnes Cullen L; Schmidt MR; Morrison TG
J Virol; 2019 May; 93(9):. PubMed ID: 30760576
[TBL] [Abstract][Full Text] [Related]
36. IGF1R is an entry receptor for respiratory syncytial virus.
Griffiths CD; Bilawchuk LM; McDonough JE; Jamieson KC; Elawar F; Cen Y; Duan W; Lin C; Song H; Casanova JL; Ogg S; Jensen LD; Thienpont B; Kumar A; Hobman TC; Proud D; Moraes TJ; Marchant DJ
Nature; 2020 Jul; 583(7817):615-619. PubMed ID: 32494007
[TBL] [Abstract][Full Text] [Related]
37. Dual Inhibition of Human Parainfluenza Type 3 and Respiratory Syncytial Virus Infectivity with a Single Agent.
Outlaw VK; Bottom-Tanzer S; Kreitler DF; Gellman SH; Porotto M; Moscona A
J Am Chem Soc; 2019 Aug; 141(32):12648-12656. PubMed ID: 31268705
[TBL] [Abstract][Full Text] [Related]
38. Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2.
Rallabhandi P; Phillips RL; Boukhvalova MS; Pletneva LM; Shirey KA; Gioannini TL; Weiss JP; Chow JC; Hawkins LD; Vogel SN; Blanco JC
mBio; 2012; 3(4):. PubMed ID: 22872782
[TBL] [Abstract][Full Text] [Related]
39. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
[TBL] [Abstract][Full Text] [Related]
40. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection.
Srikiatkhachorn A; Braciale TJ
J Exp Med; 1997 Aug; 186(3):421-32. PubMed ID: 9236194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
